Ketamine Usage Effectivity on Treatment-Resistant Depression Diagnosed Patients: a Scoping Review
Downloads
Introductions: In Indonesia, a median of 6.1% of people diagnosed with depression disorder are people over 15 years old. Only 9% of that amount underwent medical treatment, while the rest, 91%, did not undergo treatment for their depressive conditions. Inadequate and inappropriate treatment of depression will lead to Treatment-Resistant Depression (TRD). Using ketamine as a pharmacotherapy opens up new possibilities for TRD treatments. Methods: This study uses a retrospective observational study design with a systematic review approach, in which all variable data were collected from previous studies aimed at measuring the effectiveness of ketamine pharmacological therapy in patients diagnosed with treatment-resistant depression (TRD) using placebo as a benchmark of the effectiveness of ketamine in reduced clinical symptoms of TRD using secondary data in the form of study results and analyzes from published studies of the effectiveness of ketamine therapy. Results: Administration of ketamine at doses of 0.4 mg/kg and 0.5 mg/kg is more effective as an antidepressant compared to placebo in adults and is effective in the elderly at doses above 0.2 mg/kg with a maximal effect at 24 hours post-administration and disappeared by about 7 days post-administration. Conclusions: The administration of ketamine therapy is more effective at reducing depressive symptoms in diagnosed patients (TRD) than the use of placebo and repeated administration of ketamine can increase the likelihood that TRD sufferers respond to therapy and experience remission.
World Health Organization (WHO), "Depression.” https://www.who.int/health-topics/depression#tab=tab_1 (accessed Nov. 07, 2021).
"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.,” Lancet (London, England), vol. 392, no. 10159, pp. 1789–1858, Nov. 2018, doi: 10.1016/S0140-6736(18)32279-7.
Kementerian Kesehatan Republik Indonesia, "HASIL UTAMA RISKESDAS 2018 Kesehatan [Main Result of Basic Heatlh Research],” Riskesdas, p. 52, 2018, [Online]. Available: http://www.depkes.go.id/resources/download/info-terkini/materi_rakorpop_2018/Hasil Riskesdas 2018.pdf.
D. Voineskos, Z. J. Daskalakis, and D. M. Blumberger, "Management of Treatment-Resistant Depression: Challenges and Strategies.,” Neuropsychiatr. Dis. Treat., vol. 16, pp. 221–234, 2020, doi: 10.2147/NDT.S198774.
A. Little, "Treatment-resistant depression.,” Am. Fam. Physician, vol. 80, no. 2, pp. 167–172, Jul. 2009.
M. Fava et al., "Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).,” Mol. Psychiatry, vol. 25, no. 7, pp. 1592–1603, Jul. 2020, doi: 10.1038/s41380-018-0256-5.
J. L. Phillips et al., "Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.,” Am. J. Psychiatry, vol. 176, no. 5, pp. 401–409, May 2019, doi: 10.1176/appi.ajp.2018.18070834.
R. Lai et al., "Pilot dose-response trial of I.V. ketamine in treatment-resistant depression,” World J. Biol. Psychiatry, vol. 15, no. 7, pp. 579–584, 2014, doi: 10.3109/15622975.2014.922697.
T. P. Su et al., "Dose-related effects of adjunctive ketamine in taiwanese patients with treatment-resistant depression,” Neuropsychopharmacology, vol. 42, no. 13, pp. 2482–2492, 2017, doi: 10.1038/npp.2017.94.
J. W. Murrough et al., "Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.,” Am. J. Psychiatry, vol. 170, no. 10, pp. 1134–1142, Oct. 2013, doi: 10.1176/appi.ajp.2013.13030392.
D. George et al., "Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.,” Am. J. Geriatr. psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry, vol. 25, no. 11, pp. 1199–1209, Nov. 2017, doi: 10.1016/j.jagp.2017.06.007.
Y. Xu et al., "Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis.,” Int. J. Neuropsychopharmacol., vol. 19, no. 4, Apr. 2016, doi: 10.1093/ijnp/pyv124.
S. M. Szymkowicz, N. Finnegan, and R. M. Dale, "Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder.,” Journal of clinical psychopharmacology, vol. 34, no. 2. pp. 285–286, Apr. 2014, doi: 10.1097/JCP.0000000000000090.
L. Ibrahim et al., "Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression.,” Prog. Neuropsychopharmacol. Biol. Psychiatry, vol. 35, no. 4, pp. 1155–1159, Jun. 2011, doi: 10.1016/j.pnpbp.2011.03.019.
P. R. Shiroma et al., "Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.,” J. Affect. Disord., vol. 155, pp. 123–129, Feb. 2014, doi: 10.1016/j.jad.2013.10.036.
C. Andrade, "It is illegal to post this copyrighted PDF on any website . Patches : Established and Emerging Transdermal Treatments in Psychiatry You are prohibited from making this PDF publicly available . It is illegal to post this copyrighted PDF on any website .,” vol. 10970, no. August, pp. 2–4, 2019.
R.-J. Liu, F. S. Lee, X.-Y. Li, F. Bambico, R. S. Duman, and G. K. Aghajanian, "Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex.,” Biol. Psychiatry, vol. 71, no. 11, pp. 996–1005, Jun. 2012, doi: 10.1016/j.biopsych.2011.09.030.
G. Laje et al., "Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients.,” Biological psychiatry, vol. 72, no. 11. pp. e27-8, Dec. 2012, doi: 10.1016/j.biopsych.2012.05.031.
R. M. Berman et al., "Antidepressant effects of ketamine in depressed patients.,” Biol. Psychiatry, vol. 47, no. 4, pp. 351–354, Feb. 2000, doi: 10.1016/s0006-3223(99)00230-9.
Copyright (c) 2024 Satrio Wahyu Nugroho
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. Copyright of this journal is possession of the Author, by the knowledge of the Editorial Board and Journal Manager, while the moral right of the publication belongs to the author.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The articles are published under a Creative Commons Attribution Share-Alike (CC BY-SA) license. Many research funding bodies prefer the CC BY-SA license because it allows for maximum dissemination and re-use of open access materials. Users are free to share (copy, distribute, and transmit) and remix (adapt) the contribution under this license, including for commercial purposes, as long as they attribute the contribution in the manner specified by the author or licensor.
